4D Molecular Therapeutics, Inc. (FDMT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 22.18%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 22.18% | Share-based compensation / revenue. Period ending 2026-06-30. $20.41M ÷ $92.01M × 100 ≈ 22.18% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 92.01M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 20.41M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -197.12M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $92.01M | $20.41M | $-197.12M | (m) | (m) | 22.18% | (m) | (m) |
| 2026-03-31 | (m) | $88.24M | $19.48M | $-179.55M | (m) | (m) | 22.08% | (m) | (m) |
| 2025-12-31 | (m) | $85.21M | $22.02M | $-159.55M | (m) | (m) | 25.84% | (m) | (m) |
| 2025-09-30 | (m) | $120.00K | $24.04M | $-230.38M | (m) | (m) | 20034.17% | (m) | (m) |
| 2025-06-30 | (m) | $33.00K | $26.01M | $-220.33M | (m) | (m) | 78824.24% | (m) | (m) |
| 2025-03-31 | (m) | $23.00K | $27.13M | $-203.33M | (m) | (m) | 117947.83% | (m) | (m) |
| 2024-12-31 | (m) | $37.00K | $26.12M | $-187.84M | (m) | (m) | 70583.78% | (m) | (m) |
| 2024-09-30 | (m) | $17.00K | $24.45M | $-168.38M | (m) | (m) | 143829.41% | (m) | (m) |
| 2024-06-30 | (m) | $20.22M | $22.52M | $-131.22M | (m) | (m) | 111.40% | (m) | (m) |
| 2024-03-31 | (m) | $20.45M | $21.42M | $-120.90M | (m) | (m) | 104.72% | (m) | (m) |
| 2023-12-31 | (m) | $20.72M | $19.66M | $-112.87M | (m) | (m) | 94.89% | (m) | (m) |
| 2023-09-30 | (m) | $21.99M | $18.10M | $-104.94M | (m) | (m) | 82.30% | (m) | (m) |
| 2023-06-30 | (m) | $2.29M | $18.06M | $-117.45M | (m) | (m) | 790.20% | (m) | (m) |
| 2023-03-31 | (m) | $2.21M | $17.41M | $-113.75M | (m) | (m) | 788.45% | (m) | (m) |
| 2022-12-31 | (m) | $3.13M | $17.12M | $-110.03M | (m) | (m) | 547.17% | (m) | (m) |
| 2022-09-30 | (m) | $1.97M | $16.51M | $-106.08M | (m) | (m) | 836.17% | (m) | (m) |
| 2022-06-30 | (m) | $2.84M | $15.91M | $-102.24M | (m) | (m) | 560.18% | (m) | (m) |
| 2022-03-31 | (m) | $17.26M | $15.40M | $-81.41M | (m) | (m) | 89.26% | (m) | (m) |
| 2021-12-31 | (m) | $18.04M | $13.80M | $-71.33M | (m) | (m) | 76.50% | (m) | (m) |
| 2021-09-30 | (m) | $16.97M | $11.79M | $-66.99M | (m) | (m) | 69.45% | (m) | (m) |
| 2021-06-30 | (m) | $23.02M | $9.01M | $-52.15M | (m) | (m) | 39.13% | (m) | (m) |
| 2021-03-31 | (m) | $11.95M | $6.23M | $-59.70M | (m) | (m) | 52.13% | (m) | (m) |
| 2020-12-31 | (m) | $13.36M | $4.98M | $-56.66M | (m) | (m) | 37.30% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $6.96M | $3.54M | $-50.76M | (m) | (m) | 50.88% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |